{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"6.7","value":"5.5"},{"comment":"Median duration of response could not be calculated because there were not enough participants with a CR or PR.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters \\[e.g., percent change from Baseline\\]) was defined as the time from the first documented evidence of a PR or CR until the first documented sign of PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. NA indicates that data is not available.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomly assigned to receive oral GSK2118436 150 mg BID. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Participants continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study. Participants who experienced investigator-reported DP but were benefitting from study treatment were permitted to continue GSK2118436 treatment upon approval of the GlaxoSmithKline Medical Monitor.","id":"OG000","title":"GSK2118436 150 mg BID"},{"description":"In the RP, participants received IV DTIC 1000 mg/m\\^2 every 3 weeks. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Participants continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study.","id":"OG001","title":"DTIC 1000 mg/m^2 in RP"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only participants with a confirmed CR or PR were assessed for duration of response.","reportingStatus":"POSTED","timeFrame":"Time from the first documented evidence of PR or CR until the first documented sign of disease progression or death due to any cause (up to 7.4 months)","title":"Duration of Response as Assessed by an Independent Radiologist: Randomized Phase","type":"SECONDARY","unitOfMeasure":"Months"}